ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,738.52
-1.78%
US Tech 100
19,620.80
-2.29%
다우존스 지수
42,579.08
-0.99%
Bitcoin
87,488.26
-2.72%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Coya Therapeutics Inc (COYA) 시세

Coya Therapeutics Inc

Coya Therapeutics Inc (COYA)

NASDAQ
6.29
-0.23
(-3.53%)
마감 07 3월 6:00AM
15분 지연
6.29
0.00
(0.00%)
시간외 거래: 7:57AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
6.29
매수가
6.19
매도가
7.78
거래량
53,092
6.2732 일간 변동폭 6.72
4.75 52주 범위 10.6899
market_cap
105.09M
전일 종가
6.52
개장가
6.52
최근 거래 시간
60
@
6.5
마지막 거래 시간
재정 규모
US$ 347,700
VWAP
6.549
평균 볼륨(3m)
84,334
발행 주식
16,707,441
배당수익률
-
주가수익률
-13.37
주당순이익(EPS)
-0.48
매출
6M
순이익
-7.99M

Coya Therapeutics Inc 정보

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-de... Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.coyatherapeutics.com
본부
Wilmington, Delaware, USA
설립됨
-
Coya Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker COYA. The last closing price for Coya Therapeutics was US$6.52. Over the last year, Coya Therapeutics shares have traded in a share price range of US$ 4.75 to US$ 10.6899.

Coya Therapeutics currently has 16,707,441 shares in issue. The market capitalisation of Coya Therapeutics is US$108.93 million. Coya Therapeutics has a price to earnings ratio (PE ratio) of -13.37.

COYA 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 2월 2025
COYA (-3.53%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 2월 2025
COYA (-3.53%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
31 1월 2025
COYA (-3.53%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
13 1월 2025
COYA (-3.53%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
13 1월 2025
COYA (-3.53%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
13 1월 2025
COYA (-3.53%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.294.8333333333368.295.8551747066.9905021CS
4-0.81-11.40845070427.18.295.8051388426.66500762CS
12-0.0089-0.141294511746.29898.295.1843346.28743393CS
260.243.966942148766.0510.245.1832856.83253744CS
52-3.44-35.35457348419.7310.68994.75738987.43455294CS
1561.5432.42105263164.7510.68993.21698156.45050254CS
2601.5432.42105263164.7510.68993.21698156.45050254CS

COYA - Frequently Asked Questions (FAQ)

What is the current Coya Therapeutics share price?
The current share price of Coya Therapeutics is US$ 6.29
How many Coya Therapeutics shares are in issue?
Coya Therapeutics has 16,707,441 shares in issue
What is the market cap of Coya Therapeutics?
The market capitalisation of Coya Therapeutics is USD 108.93M
What is the 1 year trading range for Coya Therapeutics share price?
Coya Therapeutics has traded in the range of US$ 4.75 to US$ 10.6899 during the past year
What is the PE ratio of Coya Therapeutics?
The price to earnings ratio of Coya Therapeutics is -13.37
What is the cash to sales ratio of Coya Therapeutics?
The cash to sales ratio of Coya Therapeutics is 17.79
What is the reporting currency for Coya Therapeutics?
Coya Therapeutics reports financial results in USD
What is the latest annual turnover for Coya Therapeutics?
The latest annual turnover of Coya Therapeutics is USD 6M
What is the latest annual profit for Coya Therapeutics?
The latest annual profit of Coya Therapeutics is USD -7.99M
What is the registered address of Coya Therapeutics?
The registered address for Coya Therapeutics is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Coya Therapeutics website address?
The website address for Coya Therapeutics is www.coyatherapeutics.com
Which industry sector does Coya Therapeutics operate in?
Coya Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PSTVPlus Therapeutics Inc
US$ 1.46
(317.14%)
357.55M
AGMHAGM Group Holdings Inc
US$ 0.213
(108.21%)
690.72M
LZMHLZ Technology Holdings Ltd
US$ 9.79
(33.56%)
576.65k
TNXPTonix Pharmaceuticals Holding Corporation
US$ 14.62
(33.39%)
15.92M
GVVisionary Holdings Inc
US$ 4.89
(32.34%)
134.05M
BLNEEastside Distilling Inc
US$ 0.7846
(-89.40%)
12.25k
ACONAclarion Inc
US$ 1.5501
(-77.86%)
51.53M
ELABPMGC Holdings Inc
US$ 0.7132
(-42.02%)
1.51M
SNBRSleep Number Corporation
US$ 7.49
(-41.89%)
4.56M
CCLDCareCloud Inc
US$ 2.0904
(-33.00%)
1.23M
AGMHAGM Group Holdings Inc
US$ 0.213
(108.21%)
694.71M
PSTVPlus Therapeutics Inc
US$ 1.46
(317.14%)
359.59M
NVDANVIDIA Corporation
US$ 110.57
(-5.74%)
321.25M
GVVisionary Holdings Inc
US$ 4.89
(32.34%)
135.24M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.75
(-11.38%)
134.95M

COYA Discussion

게시물 보기
FooBarAndGrill FooBarAndGrill 3 일 전
Coya Therapeutics (COYA): BTIG Buy $15 PT March 2nd, 2025
https://coyatherapeutics.wordpress.com/2025/03/02/coya-therapeutics-coya-btig-buy-15-pt-march-2nd-2025/
👍️0
FooBarAndGrill FooBarAndGrill 4 주 전
Coya reports good results.
https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Reports-Statistically-Significant-Improvement-of-Inflammatory-Blood-Markers-in-Patients-with-Alzheimers-Disease-Following-Monthly-Dosing-with-Low-Dose-IL-2-Further-Supporting-Clinical-Development/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 1 월 전
Coya announces the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/95283171/coya-therapeutics-announces-pipeline-expansion-c
👍️0
FooBarAndGrill FooBarAndGrill 3 월 전
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
Dec 18, 2024
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Provides-Enrollment-Update-of-the-Investigator-Initiated-Phase-1-Study-of-Low-Dose-Interleukin-2-LD-IL-2--CTLA4-Ig-Fusion-Protein-in-Patients-with-Frontotemporal-Dementia-FTD/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 3 월 전
Worth a listen:
https://wsw.com/webcast/evercore44/register.aspx?conf=evercore44&page=coya&url=https://wsw.com/webcast/evercore44/coya/2360484
👍️0
FooBarAndGrill FooBarAndGrill 3 월 전
Q&A with Coya's new CEO.
https://houston.innovationmap.com/coya-therapeutics-arun-swaminathan-ceo-2670009696.html
👍️0
FooBarAndGrill FooBarAndGrill 4 월 전
Web/Con Tuesday, October 29, at 8am ET
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=xpdYyUGI
or Dial: 1-866-807-9684
https://www.businesswire.com/news/home/20241028411053/en/
👍️0
FooBarAndGrill FooBarAndGrill 4 월 전
Two events next week in Madrid (ADDF followed by CTAD)
Agenda ADDF Summit 2024 COYA presenting.
https://summit.alzdiscovery.org/agenda
👍️0
FooBarAndGrill FooBarAndGrill 4 월 전
Clinical Trials Results Poster P027 by Stanley Appel CTAD 2024
https://www.ctad-alzheimer.com/files/files/PROGRAM_CTAD2024_WEB%20OCTOBER%2018.pdf
👍️0
FooBarAndGrill FooBarAndGrill 4 월 전
1,379,314 shares Private placement @$7.25
8K https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524240775/d877895d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 5 월 전
Positive piece from H.C.Wainwright
https://coyatherapeutics.wordpress.com/2024/09/16/coya-therapeutics-coya-h-c-wainwright-buy-18-pt-engaging-immunomudulation-in-nuerology/
👍️0
FooBarAndGrill FooBarAndGrill 5 월 전
Positive piece published by Seeking Alpha
https://seekingalpha.com/article/4726428-coya-therapeutics-several-near-term-share-price-appreciation-catalysts
👍️0
FooBarAndGrill FooBarAndGrill 5 월 전
Coya announces that CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will participate in a fireside chat at the Chardan 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:00pm ET.
👍️0
Monksdream Monksdream 6 월 전
COYA under $7

👍️0
FooBarAndGrill FooBarAndGrill 6 월 전
Rarely do I see pre-market volume. 2K so far today. Nice.
👍️0
FooBarAndGrill FooBarAndGrill 7 월 전
Officers come and go. On August 19, 2024, Coya Therapeutics, Inc. (the “Company”) announced a planned change in management. Effective November 1, 2024, Arun Swaminathan, the Company’s Chief Business Officer since April 2023, will serve as Chief Executive Officer of the Company. Dr. Swaminathan will succeed Dr. Howard Berman, who, on August 16, 2024, notified the Company that he would be resigning as Chief Executive Officer of the Company effective at the close of business on October 31, 2024. After his resignation, Dr. Berman intends to remain a member of the Company’s board of directors (the “Board”) and serve as Executive Chairman of the Board. Upon his resignation, the Company anticipates that it will enter a consulting agreement with Dr. Berman, with an expected term of 12 months, pursuant to which Dr. Berman will provide consulting services to the Company.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524202551/d861081d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 7 월 전
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Expands-Pipeline-and-Intellectual-Property-Portfolio-with-Filing-of-New-U.S.-Patents-for-COYA-301-in-Combination-with-Glucagon-Like-Peptide-1-GLP-1-Receptor-Agonists/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 7 월 전
COYA to present AD results at CTAD24
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-that-Results-from-a-Double-Blind-Placebo-Controlled-Study-in-Alzheimers-Disease-will-be-presented-on-October-29-2024-at-the-Clinical-Trials-on-Alzheimers-Disease-Conference-CTAD24-in-Madrid/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 8 월 전
Coya 8K July 15
On June 14, 2024, Coya Therapeutics, Inc. (the “Company”) submitted to the U.S. Food and Drug Administration (the “FDA”) an Investigational New Drug Application (the “IND”) seeking to initiate a study entitled “Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label Extension (OLE) to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)” (the “Study”). On July 12, 2024, the Company received an email notification from the FDA stating that additional non-clinical data is required prior to the initiation of the Study. The FDA also stated that it would provide the Company with more details about what additional information it requires within the next thirty (30) days.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524178809/d762748d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 9 월 전
The WOW signal!
Prior to initiating treatment, patients were declining at an average rate of -1.1 points per month on the ALSFRS-R rating scale- At the end of 6 months of treatment, the mean rate of change on the ALSFRS-R was +0.04 points per month.
👍️0
FooBarAndGrill FooBarAndGrill 9 월 전
$COYA ALS Peer-Reviewed Publication:
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1415106/full
👍️0
FooBarAndGrill FooBarAndGrill 9 월 전
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology. A portion of the data from the manuscript was previously presented at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93970259/coya-therapeutics-announces-acceptance-of-peer-rev
👍️0
FooBarAndGrill FooBarAndGrill 9 월 전
Today 2 Jun is #LouGehrigDay #EndALS
👍️0
FooBarAndGrill FooBarAndGrill 9 월 전
It’s T+1 time
👍️0
FooBarAndGrill FooBarAndGrill 10 월 전
On May 17, 2024, Coya Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Alzheimer’s Drug Discovery Foundation (the “ADDF”) for the issuance and sale in a private placement (the “Private Placement”) of 603,136 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $8.29 per share for gross proceeds to the Company of $5.0 million.
ADDF >>>> https://www.alzdiscovery.org/
8K >>>>>>> https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524142950/d820823d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
$COYA Therapeutics has posted several YT videos.
https://www.youtube.com/@coyatherapeutics7911/videos
👍️0
FooBarAndGrill FooBarAndGrill 10 월 전
Validating A Better ALS Biomarker With Coya's Fred Grossman
Fred discusses $COYA's 1H2024 plans for a IND application and the 2H2024 P2 trial.
https://www.clinicalleader.com/doc/validating-a-better-als-biomarker-with-coya-s-fred-grossman-0001
👍️0
FooBarAndGrill FooBarAndGrill 11 월 전
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-to-Participate-in-the-3rd-Annual-ALS-Drug-Development-Summit/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 11 월 전
And in the world of ALS.
Amylyx Pharmaceuticals said it would voluntarily remove its drug for amyotrophic lateral sclerosis from the market, a rare move that comes less than a month after a clinical trial showed its once-promising treatment for the fatal disease doesn’t work.
https://www.washingtonpost.com/business/2024/04/04/amylyx-als-drug/
👍️0
FooBarAndGrill FooBarAndGrill 12 월 전
Investing in the fight against ALS. Hosted by Schwab Network.
https://schwabnetwork.com/video/investing-in-the-fight-against-als
👍️0
FooBarAndGrill FooBarAndGrill 12 월 전
COYA 2023 10-K
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000095017024033161/coya-20231231.htm
👍️0
FooBarAndGrill FooBarAndGrill 12 월 전
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000095017024033159/coya-20240319.htm
👍️0
FooBarAndGrill FooBarAndGrill 12 월 전
Neuroimmune Pharmacology Conference Powerpoint
https://s201.q4cdn.com/307844724/files/doc_news/2024/NeuroimmunePharmacology3-12-2024-4.pdf
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
Dr. Stan Appel will be presenting during a 30-minute segment at the The 28th Society of Neuroimmune Pharmacology Conference.
March 10-13, 2024 The Francis Marion Hotel, Charleston
https://s-nip.org/documents/2024/SNIP_2024_Schedule.pdf
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
Empowering Patient Story and Coya’s Fight Against Neurodegenerative Diseases
Coya’s VP of Operations and Patient Advocacy, Daniel Barvin, had the opportunity to shed light on the world of his empowering patient story and Coya’s fight against neurodegenerative diseases in Houston for the Reel Abilities, UP Abilities event.
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
21 Feb: COYA letter to stockholders.
Today, we announce that we are further expanding the pipeline for COYA 302, adding Alzheimer’s disease (AD) to its growing list of indications
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93327358/coya-therapeutics-issues-letter-to-stockholders-hi
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
About ALS:
ALS is a progressive disease, meaning the symptoms get worse over time. The functional status of ALS patients declines about 1 point per month on average, as measured by the Revised ALS Function Rating Scale1, or ALSFRS-R, a validated tool to monitor the progression of the disease.

COYA results:
Patients' disease progression was measured using the ALSFRS-R scale. The mean scores after initiation of treatment were not statistically different compared to the score at baseline, suggesting significant amelioration in the progression of the disease over the 48-week treatment period.

https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93265319/coya-therapeutics-licenses-intellectual-property-r
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
SEC Form 4's
$COYA announced small option grants (5000 shr @ $7.41) for 3 BOD members. I expect more announcements to come.
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
8K 19 Jan 2024
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524010775/d732822d8k.htm
As of December 31, 2023, Coya Therapeutics, Inc. (the “Company”) had cash and cash equivalents (unaudited) of $32.6 million. In January 2024, the Company received $7.5 million from Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”), as required under the terms of the Development and License Agreement entered into with Dr. Reddy’s on December 5, 2023, which was previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023 (the “Form 8-K”).

The Company’s cash and cash equivalents as of December 31, 2023, pro forma for receipt of the $7.5 million from Dr. Reddy’s (as if such amount was received on December 31, 2023) would be $40.1 million.

In addition, as previously disclosed in the Form 8-K, (i) upon the first Food and Drug Administration (FDA) acceptance of an investigational new drug (IND) application for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), Dr. Reddy’s will pay the Company an additional $4.2 million, and (ii) upon dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States, Dr. Reddy’s will pay the Company an additional $4.2 million.

The Company anticipates that the IND filing will be made in the first half of 2024 and the dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States will occur in the second half of 2024.

The Company expects its cash and cash equivalents described above will be sufficient to meet its operating needs into 2026.
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
$COYA current shares in issue: 10M
A Private placement announced DEC 5 2023 added 4.4M shares + 319K warrants.
Prospectus announced today will allow those shares to trade. The 319K warrants may also be exercised.
Currently most shares are held tightly.
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
I'm not much of a predictor. And most of the shares are tightly held.
But the company does have my respect and a good outlook long term.
👍️0
Sirpeter Sirpeter 1 년 전
Where do you see the PPS heading by year end
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
Coya has a clear path towards submission of the IND application to the FDA in the second quarter of 2024, with a planned initiation of a well-controlled, double-blind clinical trial of COYA 302 in patients with ALS upon acceptance of the IND
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
Scientists solve 18-year-old mystery and find the once-elusive source of a critical T cell population
https://medicalxpress.com/news/2023-12-scientists-year-old-mystery-once-elusive-source.html
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
2023, $COYA has secured a private placement agreement plus a partnership agreement with $RDY. These two deals will provide non-dilutive financing thru 2026.
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
T-Cells are a focus of COYA research. Understanding the language is helpful.
CAR-T cells are Chimeric Antigen Receptors. (T-Cells)
Tregs are Regulatory T-Cells.
T-Cells have great potential.
‘It’s all gone’: CAR-T therapy forces autoimmune diseases into remission
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
COYA updated Pipeline.
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
$COYA $26.5M private placement.
A very newsy 8-K
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
$COYA + $RDY

New collab announced.
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
Brief Hometown Houston interview with $COYA CEO Howard Berman.
https://cw39.com/news/health/new-study-at-houston-methodist-hospital-for-alzheimers-disease/
👍️0

최근 히스토리

NASDAQ
COYA
Coya Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지